Overview

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b open-label study to investigate the safety and maximum tolerated dose of aldoxorubicin plus doxorubicin HCl adminstered as infusion every 3 weeks for up to 8 cycles in subjects with advance solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

CytRx

Treatments:

Doxorubicin
Liposomal doxorubicin